Leiner Proposes $10 Million Restitution To Enhance Its Value
This article was originally published in The Tan Sheet
Executive Summary
Leiner Health Products describes a proposed agreement with federal investigators as a key to restarting its U.S. OTC business, but the firm's debt load makes it more likely the business will be sold
You may also be interested in...
NBTY Leiner Buy Intensifies Supplement Ingredient Competition
The dietary supplement ingredient supply market is set to become more competitive with NBTY's planned acquisition of Leiner Health Products
Leiner Files For Chapter 11 Protection, Explores Selling Business
Leiner Health Products' shutdown of its U.S. OTC operations a year ago forced the firm to seek Chapter 11 bankruptcy protection and explore selling its U.S. business
Leiner’s Return To U.S. OTC Market Complicated By FDA Warning, DOJ Inquiry
FDA's investigation into manufacturing and quality control issues at Leiner Health Products' South Carolina facility revealed a culture of mismanagement that created a pattern of undetected production errors and overlooked discrepancies regarding product development, according to the agency